The fast component of the barium fluoride (BaF2) crystal luminescence with the emission peak at 220 nm allows those crystals to be employed in fast calorimeters operating in harsh radiation ...environment. However, the slow component with the emission peak at 330 nm and about 85% of the total emission light could create big problems when working at a high radiation rate. In this work we report results of tests of multilayer filters that can suppress luminescence in the range from 250 nm to 400 nm, which covers most of the BaF2 slow component luminescence. The filters are made by spraying layers of rare earth oxides on a quartz glass substrate. Filters typically comprise 200-220 layers. A few filters were prepared by spraying thin layers on quartz glass. The filters have a peak transmittance of about 70-80% in the range of 200-250 nm. Measurements of the light output of the BaF2 crystal with and without a filter between the crystal readout end and the PMT demonstrate substancial suppression of the slow component. To our knowledge, this kind of filters are produced and tested for the first time.
By using the model for subsea sediments (SSs) (Institute of Atmospheric Physics, Russian Academy of Sciences, IAP RAS) and the general circulation model in the Arctic Ocean–North Atlantic (GCM AO-NA) ...(Institute of Computational Mathematics and Mathematical Geophysics, Siberian Branch, Russian Academy of Sciences, ICMMG SB RAS), the response of the parameters of the permafrost layer and the methane hydrate stability zone (MHSZ) to external impacts in dependence on the parameters of the problem is considered: the degree of the geothermal heat flux intensity
G
at the lower (bottom) boundary of the computation domain of the permafrost layer of subsea sediments and the depth
Z
of this boundary.
Background Prevalence of DM in patients with gout is high, but the influence of glucocorticoids (GC) and inhibitors IL-1β on their carbohydrate metabolism has not been investigated thoroughly. ...Anti-inflammatory effects connected with IL-1 inhibition are supposed to decrease the risk of DM 1. Objectives To compare the effects of a single injection of canacinumab or betametazone on glucose metabolism and pro-inflammatory cytokine serum levels in patients with gout. Methods Open-label prospective randomized study of 40 patients with gout (37 m, 3 f), mean age 51,3±11,3 years, was performed. Inclusion criteria: crystal-proven gout, acute arthritis. Exclusion criteria: infections, sub- or decompensation of DM and use of anti-diabetic drugs. 20 patients received one dose of canakinumab 150 mg subcutaneously, 20 patients received one dose of betametazone 7 mg intraarticular. Basal and postprandial glucose (PPG) level was performed 120 min before injection and 24, 48 h and 14, 90 days after injection. Cytokine level was detected using of "xMAP" technology (Human Grp I Cytokine 27-plex panel) and on the analyzer "BioPlex-200" (Bio-Rad, the USA) before injection and 14 and 90 days after injection. Glycosylated hemoglobin (HbA1c) was determined by borate affinity assay. Results At baseline, glycemic levels (basal, PPG), HbA1c and cytokines in both groups were identical. Glycemic level ≥6,1 mmol/l and or PPG ≥11,1 mmol/l was detected in all patients injected betametazone in 24 hours, in 6 patients in 48 hours, in 4 patients in 14 days and in 3 patients in 90 days after the injection. There were no patients in study who were injected canacinumab with glycemic level ≥6,1 mmol/l and/or PPG ≥11,1 mmol/l. HbA1c level in a betametazone group in 90 days increased (from 5,83±0,49% to 6,01±0,60%), and on the contrary, in a canacinumab group decreased (from 5,75±0,55% to 5,61±0,50%), but the difference was not accurate. In a canacinumab group serum levels of IL-1β and IL-6 positively decreased on 14th and 90th days of study. Serum level of other cytokines in groups during the study did not change fundamentally. Conclusions In patients with gout who take intraarticular injections of GC, the risk of DM progression can be underestimated. In contrast, canacinumab taking can be connected with decreasing the risk of DM through the influence on the levels of IL-1β and IL-6. To study the influence of the medicines on carbohydrate metabolism further research is needed. References Noe A., Howard C., Thuren T. and al. Pharmacokinetic and Pharmacodynamic Characteristics of Single-dose Canakinumab in Patients With Type 2 Diabetes Mellitus. Clin Ther. 2014;36(11):1625-37. Disclosure of Interest None declared
A synthetic supramolecular system is described that models the effect of phosphoryl transfer in molecular recognition. β-Cyclodextrin-6A-phosphate (pCD), which is shown to be a substrate of alkaline ...phosphatase, binds cationic aromatic guests, including anticancer agents, up to 100-fold better than native β-CD. The above observations demonstrate that pCD is capable of releasing the guests from its cavity upon hydrolysis with the phosphatase, as also confirmed by monitoring the hydrolysis in the presence of a guest.
PDF
